← Back to home

NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION WITHOUT POLYPOIDAL CHOROIDAL VASCULOPATHY

Clinical trials for NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION WITHOUT POLYPOIDAL CHOROIDAL VASCULOPATHY explained in plain language.

Never miss a new study

Get alerted when new NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION WITHOUT POLYPOIDAL CHOROIDAL VASCULOPATHY trials appear

Sign up with your email to follow new studies for NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION WITHOUT POLYPOIDAL CHOROIDAL VASCULOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New pill may boost vision in wet AMD patients

Disease control Recruiting now

This Phase 3 trial tests whether adding an SMZ1 tablet to standard ranibizumab eye injections improves vision more than injections alone in people with wet age-related macular degeneration (AMD). Participants receive either SMZ1 or a placebo tablet twice daily for 12 months, alon…

Matched conditions: NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION WITHOUT POLYPOIDAL CHOROIDAL VASCULOPATHY

Phase: PHASE3 • Sponsor: SANGMYUNG innovation • Aim: Disease control

Last updated Jul 12, 2026 00:00 UTC

NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION WITHOUT POLYPOIDAL CHOROIDAL VASCULOPATHY

Get alerted when new NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION WITHOUT POLYPOIDAL CHOROIDAL VASCULOPATHY trials appear

New pill may boost vision in wet AMD patients